Skip to content

Silence Therapeutics

US · SLN #3615 by market cap
9.39 -0.43 -4.38%
Live - 5344 symbols - heartbeat 261s ago · 2026-10-08 10:00
Pre-market 9.95 +1.32%
After-hours 9.82 0.00%
Market cap
583.63M
P/B
15.17
EPS
-1.89
Reader sentiment Are you bullish or bearish on SLN?

Anonymous reader poll. Unscientific, not investment advice.

Analyst consensus 5 analysts

Buy
Avg price target 37.00 +294.0%
Price target rangecurrent 9.39
Low4.00
Avg37.00
High75.00
Buy 80% Hold 0% Sell 20%
Recent ratings (25)
DateFirmAnalystRatingTarget
2026-09-21 H.C. Wainwright -- BUY 75.00
2026-09-10 William Blair -- BUY --
2026-08-16 Chardan Capital -- BUY --
2026-08-14 H.C. Wainwright -- BUY 75.00
2026-08-11 Morgan Stanley -- BUY 32.00
2026-08-11 H.C. Wainwright -- BUY 75.00
2026-08-10 Chardan Capital -- BUY 27.00
2026-08-10 William Blair -- BUY --
2026-08-10 Morgan Stanley -- BUY 32.00
2026-08-10 H.C. Wainwright -- BUY 75.00
2026-07-27 Goldman Sachs -- SELL 4.00
2026-06-24 Cantor Fitzgerald -- BUY --
2026-06-11 William Blair -- BUY --
2026-06-11 Morgan Stanley -- BUY 25.00
2026-06-02 Morgan Stanley -- BUY 25.00
2026-05-29 Morgan Stanley -- BUY 25.00
2026-05-07 Chardan Capital -- BUY 27.00
2026-04-29 H.C. Wainwright -- BUY 75.00
2026-03-06 William Blair -- BUY --
2026-03-06 Morgan Stanley -- BUY 25.00
2026-03-05 Chardan Capital -- BUY 35.00
2026-03-05 Goldman Sachs -- SELL 4.00
2026-03-02 William Blair -- BUY --
2025-11-04 William Blair -- BUY --
2025-10-16 William Blair -- BUY --

Price target trend monthly average, last 3 years

Earnings history price reaction on the day

PeriodReport dateSessionOptions expectedActual move
2024/Q4 2025-02-27 -- ±21.59% -1.05% (in line)
2023/Q4 2024-03-13 -- -- -1.12%
2022/Q4 2023-03-15 -- -- -5.18%
2021/Q4 2022-03-17 -- -- -1.71%
2021/Q2 2021-08-12 -- -- +0.00%
2020/Q4 2021-03-30 -- -- +0.00%
2020/Q2 2020-09-14 -- -- +0.00%

"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.

Quote time 2026-10-08 10:00:12 · For reference only, not investment advice and not tailored to your situation.